LEADER 04538nam 22006015 450 001 9910254261203321 005 20200702092843.0 010 $a3-319-27016-8 024 7 $a10.1007/978-3-319-27016-6 035 $a(CKB)3710000000579426 035 $a(EBL)4356747 035 $a(SSID)ssj0001607006 035 $a(PQKBManifestationID)16314680 035 $a(PQKBTitleCode)TC0001607006 035 $a(PQKBWorkID)14896689 035 $a(PQKB)11109513 035 $a(DE-He213)978-3-319-27016-6 035 $a(MiAaPQ)EBC4356747 035 $a(PPN)19170069X 035 $a(EXLCZ)993710000000579426 100 $a20160125d2016 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aManagement of Chemotherapy-Induced Nausea and Vomiting $eNew Agents and New Uses of Current Agents /$fedited by Rudolph M. Navari 205 $a1st ed. 2016. 210 1$aCham :$cSpringer International Publishing :$cImprint: Adis,$d2016. 215 $a1 online resource (187 p.) 300 $aDescription based upon print version of record. 311 $a3-319-27014-1 320 $aIncludes bibliographical references at the end of each chapters. 327 $a1. Introduction -- 2. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anti-Cancer Chemotherapy in Humans -- 3. First Generation 5HT-3 Receptor Antagonists -- 4. Second Generation Serotonin (5-HT3) Receptor Antagonist Palonosetron -- 5. The Role of Neurokinin-1 Receptor Antagonists in CINV -- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting -- 7. Gabapentin for the Prevention of CINV -- 8. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy -- 9. Clinical Management of CINV -- 10. Treatment of Chemotherapy-Induced Nausea -- 11. Conclusions -- 12. Future Directions. 330 $aThis book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients? perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy. 606 $aOncology   606 $aPharmacology 606 $aPharmacotherapy 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 606 $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000 615 0$aOncology  . 615 0$aPharmacology. 615 0$aPharmacotherapy. 615 14$aOncology. 615 24$aPharmacology/Toxicology. 615 24$aPharmacotherapy. 676 $a610 702 $aNavari$b Rudolph M$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910254261203321 996 $aManagement of Chemotherapy-Induced Nausea and Vomiting$92519686 997 $aUNINA